{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+2%EF%BC%9AB-cell+Malignancies", "query": { "condition": "Part 2：B-cell Malignancies" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Part+2%EF%BC%9AB-cell+Malignancies&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T13:12:19.690Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Solid Tumor", "Refractory Solid Tumor" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Dinutuximab", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2020-11-09", "completion_date": "2025-08-19", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04238819" }, { "nct_id": "NCT03028103", "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Lymphoma", "Mantle Cell Lymphoma", "Advanced Solid Tumor", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-03-27", "completion_date": "2019-11-29", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 3, "location_summary": "Tucson, Arizona • Tampa, Florida • New York, New York", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03028103" }, { "nct_id": "NCT00923169", "title": "Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Anti-Transforming Growth Factor-beta (GC 1008)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2006-07-09", "completion_date": "2010-01-20", "has_results": false, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 1, "location_summary": "Little Brunswick, New Jersey", "locations": [ { "city": "Little Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923169" }, { "nct_id": "NCT01457417", "title": "A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Solid Tumors", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "DKN-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 32, "start_date": "2012-01", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2016-09-28", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Albany, New York • Greenville, South Carolina + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Albany", "state": "New York" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Dallas", "state": "Texas" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457417" }, { "nct_id": "NCT00478725", "title": "Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "GW786034, oral", "type": "DRUG" }, { "name": "GW786034, IV", "type": "DRUG" }, { "name": "GW786034, radiolabeled oral", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2007-07-18", "completion_date": "2008-07-01", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Nashville, Tennessee", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478725" }, { "nct_id": "NCT04014205", "title": "A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Part 1：r/r B-cell Malignancies", "Part 2：B-cell Malignancies" ], "interventions": [ { "name": "Orelabrutinib (ICP-022)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beijing InnoCare Pharma Tech Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2019-11-18", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Anaheim, California • Los Angeles, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04014205" }, { "nct_id": "NCT05121103", "title": "A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma, Refractory", "Diffuse Large B-Cell Lymphoma", "Diffuse Large B Cell Lymphoma Refractory", "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "EZM0414", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-05-31", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 8, "location_summary": "Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05121103" }, { "nct_id": "NCT05533775", "title": "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mature B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Months to 30 Years" }, "enrollment_count": 65, "start_date": "2022-11-16", "completion_date": "2032-11-30", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Oakland, California • Roseville, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05533775" }, { "nct_id": "NCT01955668", "title": "AZD6738 First Time in Patient Multiple Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),", "Prolymphocytic Leukaemia (PLL)", "B Cell Lymphomas" ], "interventions": [ { "name": "Administration of AZD6738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-11", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-06-19", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01955668" }, { "nct_id": "NCT04543188", "title": "A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma", "Carcinoma, Non-Small-Cell Lung", "Brain Neoplasms, Primary", "Brain Neoplasms", "Malignant Neoplasms" ], "interventions": [ { "name": "PF-07284890", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 65, "start_date": "2021-01-08", "completion_date": "2024-03-20", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-29T13:12:19.690Z", "location_count": 39, "location_summary": "Duarte, California • San Francisco, California • Orlando, Florida + 23 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04543188" } ] }